Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection
Ruikang Liu, Jeffrey L. Americo, Catherine A. Cotter, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 12
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Viral Vector Vaccine Development and Application during the COVID-19 Pandemic
Shaofeng Deng, Hui Liang, Chen Pin, et al.
Microorganisms (2022) Vol. 10, Iss. 7, pp. 1450-1450
Open Access | Times Cited: 68
Natural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
David A. Meekins, Natasha N. Gaudreault, Jüergen A. Richt
Viruses (2021) Vol. 13, Iss. 10, pp. 1993-1993
Open Access | Times Cited: 93
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
Alina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 28
Open Access | Times Cited: 85
Battle Royale: Innate Recognition of Poxviruses and Viral Immune Evasion
Huibin Yu, Ryan C. Bruneau, Greg Brennan, et al.
Biomedicines (2021) Vol. 9, Iss. 7, pp. 765-765
Open Access | Times Cited: 77
A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development
Zainalabideen A. Abdulla, Sharaf M. Al-Bashir, Noor S. Al-Salih, et al.
Pathogens (2021) Vol. 10, Iss. 7, pp. 788-788
Open Access | Times Cited: 58
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection
Jeffrey L. Americo, Catherine A. Cotter, Patricia L. Earl, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 24
Open Access | Times Cited: 51
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
Flavia Chiuppesi, Vu H. Nguyen, Yoonsuh Park, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 50
Vaccinia E5 is a major inhibitor of the DNA sensor cGAS
Ning Yang, Yi Wang, Peihong Dai, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 21
Why do poxviruses still matter?
Zhilong Yang, Mark R. Gray, Lake Winter
Cell & Bioscience (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 41
Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection
Patricia Pérez, David Astorgano, Guillermo Albericio, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27
Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
Beatriz Perdiguero, Patricia Pérez, Laura Marcos-Villar, et al.
Journal of Molecular Biology (2023) Vol. 435, Iss. 15, pp. 168173-168173
Open Access | Times Cited: 20
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity
Christian Meyer zu Natrup, Alina Tscherne, Christine Dahlke, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 24
Open Access | Times Cited: 26
Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
Adrián Lázaro-Frías, Patricia Pérez, Carmen Zamora, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 25
A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection
Patricia Pérez, Adrián Lázaro-Frías, Carmen Zamora, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 23
MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters
Robbert Boudewijns, Patricia Pérez, Adrián Lázaro-Frías, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 23
Comparison of the pathogenesis of SARS-CoV-2 infection in K18-hACE2 mouse and Syrian golden hamster models
Haengdueng Jeong, Youn Woo Lee, In Ho Park, et al.
Disease Models & Mechanisms (2022) Vol. 15, Iss. 11
Open Access | Times Cited: 23
Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2
Petra Mooij, Juan García‐Arriaza, Patricia Pérez, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Animal models for SARS‐CoV‐2 infection and pathology
Zhenfei Bi, Weiqi Hong, H. J. Yang, et al.
MedComm (2021) Vol. 2, Iss. 4, pp. 548-568
Open Access | Times Cited: 29
Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic
Xue Li, Liying Zhang, Si Chen, et al.
Infection Genetics and Evolution (2021) Vol. 93, pp. 104971-104971
Open Access | Times Cited: 28
Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application
Ana Sara Cordeiro, Yogita Patil‐Sen, Maitreyi Shivkumar, et al.
Pharmaceutics (2021) Vol. 13, Iss. 12, pp. 2091-2091
Open Access | Times Cited: 28
SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern induce lethal disease in K18-hACE2 transgenic mice despite convalescent plasma therapy
Alexander M. Horspool, Chengjin Ye, Ting Y. Wong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 27
Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice
Zhenfei Bi, Weiqi Hong, Haiying Que, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 27
The Mechanisms and Animal Models of SARS-CoV-2 Infection
Wenrui Jia, Juan Wang, Bao Sun, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 24
Poxviruses and paramyxoviruses use a conserved mechanism of STAT1 antagonism to inhibit interferon signaling
Callum Talbot-Cooper, Teodors Panteļejevs, John P. Shannon, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 3, pp. 357-372.e11
Open Access | Times Cited: 17
Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice
Ting Y. Wong, Alexander M. Horspool, Brynnan P. Russ, et al.
Journal of Virology (2022) Vol. 96, Iss. 6
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top